Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Confidence

Stock Track03-28

Immatics N.V. (NASDAQ: IMTX) shares are soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst optimism. The biotechnology company has demonstrated a remarkable turnaround, moving from losses to profitability and significantly beating market expectations.

The company reported a substantial 189% year-over-year increase in revenue, reaching €155.8 million for the full year 2024. This figure exceeded analyst estimates by an impressive 39%. Moreover, Immatics achieved profitability with a net income of €15.2 million, a significant improvement from the €97.0 million loss reported in the previous year. The earnings per share (EPS) came in at €0.14, surpassing analyst projections and marking a notable turnaround from the €1.20 loss per share in 2023.

Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. This vote of confidence from a major financial institution further bolsters investor optimism in the company's future prospects. The combination of strong financial performance and sustained analyst support appears to be driving the pre-market rally in Immatics' stock price, as investors react to the company's improved market position and growth potential in the competitive biotechnology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188462239?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-28 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188462239","market":"hk","top_or_hot":-1,"title":"Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Confidence","media":"Stock Track","content":"<p>Immatics N.V. (NASDAQ: IMTX) shares are soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst optimism. The biotechnology company has demonstrated a remarkable turnaround, moving from losses to profitability and significantly beating market expectations.</p>\n\n<p>The company reported a substantial 189% year-over-year increase in revenue, reaching €155.8 million for the full year 2024. This figure exceeded analyst estimates by an impressive 39%. Moreover, Immatics achieved profitability with a net income of €15.2 million, a significant improvement from the €97.0 million loss reported in the previous year. The earnings per share (EPS) came in at €0.14, surpassing analyst projections and marking a notable turnaround from the €1.20 loss per share in 2023.</p>\n\n<p>Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. This vote of confidence from a major financial institution further bolsters investor optimism in the company's future prospects. The combination of strong financial performance and sustained analyst support appears to be driving the pre-market rally in Immatics' stock price, as investors react to the company's improved market position and growth potential in the competitive biotechnology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Immatics N.V. Soars 5.72% Pre-Market on Strong 2024 Results and Analyst Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-28 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Immatics N.V. (NASDAQ: IMTX) shares are soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst optimism. The biotechnology company has demonstrated a remarkable turnaround, moving from losses to profitability and significantly beating market expectations.</p>\n\n<p>The company reported a substantial 189% year-over-year increase in revenue, reaching €155.8 million for the full year 2024. This figure exceeded analyst estimates by an impressive 39%. Moreover, Immatics achieved profitability with a net income of €15.2 million, a significant improvement from the €97.0 million loss reported in the previous year. The earnings per share (EPS) came in at €0.14, surpassing analyst projections and marking a notable turnaround from the €1.20 loss per share in 2023.</p>\n\n<p>Adding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. This vote of confidence from a major financial institution further bolsters investor optimism in the company's future prospects. The combination of strong financial performance and sustained analyst support appears to be driving the pre-market rally in Immatics' stock price, as investors react to the company's improved market position and growth potential in the competitive biotechnology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMTX","symbol_name":"Immatics N.V.","start_time":0,"source_url":"","article_id":"1188462239","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188462239","pubTimestamp":1743169104,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Immatics N.V.  shares are soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst optimism. The biotechnology company has demonstrated a remarkable turnaround, moving from losses to profitability and significantly beating market expectations.The company reported a substantial 189% year-over-year increase in revenue, reaching 155.8 million for the full year 2024. This figure exceeded analyst estimates by an impr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMTX":"Immatics N.V."},"translate_title":"由于2024年强劲业绩和分析师信心，股票跟踪Immatics N.V.盘前飙升5.72%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMTX":1},"content_text":"Immatics N.V. (NASDAQ: IMTX) shares are soaring 5.72% in pre-market trading on Friday, following the release of its impressive full-year 2024 financial results and continued analyst optimism. The biotechnology company has demonstrated a remarkable turnaround, moving from losses to profitability and significantly beating market expectations.\nThe company reported a substantial 189% year-over-year increase in revenue, reaching €155.8 million for the full year 2024. This figure exceeded analyst estimates by an impressive 39%. Moreover, Immatics achieved profitability with a net income of €15.2 million, a significant improvement from the €97.0 million loss reported in the previous year. The earnings per share (EPS) came in at €0.14, surpassing analyst projections and marking a notable turnaround from the €1.20 loss per share in 2023.\nAdding to the positive sentiment, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Immatics with a price target of $13. This vote of confidence from a major financial institution further bolsters investor optimism in the company's future prospects. The combination of strong financial performance and sustained analyst support appears to be driving the pre-market rally in Immatics' stock price, as investors react to the company's improved market position and growth potential in the competitive biotechnology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188462239"}